A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions
Open Access
- 28 October 2011
- journal article
- Published by Springer Science and Business Media LLC in Journal of Translational Medicine
- Vol. 9 (1), 185
- https://doi.org/10.1186/1479-5876-9-185
Abstract
Prostate cancer metastasizes to bone in the majority of patients with advanced disease leading to painfully debilitating fractures, spinal compression and rapid decline. In addition, prostate cancer bone metastases often become resistant to standard therapies including androgen deprivation, radiation and chemotherapy. There are currently few models to elucidate mechanisms of interaction between the bone microenvironment and prostate cancer. It is, thus, essential to develop new patient-derived, orthotopic models. Here we report the development and characterization of PCSD1 (Prostate Cancer San Diego 1), a novel patient-derived intra-femoral xenograft model of prostate bone metastatic cancer that recapitulates mixed osteolytic and osteoblastic lesions.MethodsA femoral bone metastasis of prostate cancer was removed during hemiarthroplasty and transplanted intoRag2-/-;γc-/-mice either intra-femorally or sub-cutaneously. Xenograft tumors that developed were analyzed for prostate cancer biomarker expression using RT-PCR and immunohistochemistry. Osteoblastic, osteolytic and mixed lesion formation was measured using micro-computed tomography (microCT).ResultsPCSD1 cells isolated directly from the patient formed tumors in all mice that were transplanted intra-femorally or sub-cutaneously intoRag2-/-;γc-/-mice. Xenograft tumors expressed human prostate specific antigen (PSA) in RT-PCR and immunohistochemical analyses. PCSD1 tumors also expressed AR, NKX3.1, Keratins 8 and 18, and AMACR. Histologic and microCT analyses revealed that intra-femoral PCSD1 xenograft tumors formed mixed osteolytic and osteoblastic lesions. PCSD1 tumors have been serially passaged in mice as xenografts intra-femorally or sub-cutaneously as well as grown in culture.ConclusionsPCSD1 xenografts tumors were characterized as advanced, luminal epithelial prostate cancer from a bone metastasis using RT-PCR and immunohistochemical biomarker analyses. PCSD1 intra-femoral xenografts formed mixed osteoblastic/osteolytic lesions that closely resembled the bone lesions in the patient. PCSD1 is a new primary prostate cancer bone metastasis-derived xenograft model to study metastatic disease in the bone and to develop novel therapies for inhibiting prostate cancer growth in the bone-niche.This publication has 72 references indexed in Scilit:
- α-Methylacyl-CoA Racemase Spliced Variants and Their Expression in Normal and Malignant Prostate TissuesUrology, 2011
- Treatment and prevention of bone complications from prostate cancerBone, 2011
- Differential regulation of insulin-like growth factor-I receptor gene expression by wild type and mutant androgen receptor in prostate cancer cellsMolecular and Cellular Endocrinology, 2010
- Integrative Genomic Profiling of Human Prostate CancerCancer Cell, 2010
- Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 studyThe Lancet, 2010
- Human prostate sphere‐forming cells represent a subset of basal epithelial cells capable of glandular regeneration in vivoThe Prostate, 2009
- Functional and Evolutionary Insights into Human Brain Development through Global Transcriptome AnalysisNeuron, 2009
- Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signatureClinical & Experimental Metastasis, 2009
- Influence of simultaneous targeting of the bone morphogenetic protein pathway and RANK/RANKL axis in osteolytic prostate cancer lesion in boneBone, 2009
- The current state of preclinical prostate cancer animal modelsThe Prostate, 2008